Nature Medicine, Published online: 04 April 2025; doi:10.1038/s41591-025-03640-8
In this phase 1 trial, patients with heavily pretreated and refractory CD30+ lymphoma were safely treated with donor-cord-blood-derived NK cells that were precomplexed with the anti-CD30 and anti-CD16A bispecific antibody AFM13, showing encouraging preliminary clinical response rates.
